Articles tagged with Tumor Growth
A comprehensive analysis of over 2,200 patients in Europe reveals the complexity of cholangiocarcinoma, a rare cancer often diagnosed at an advanced stage. The study highlights the need for education programs to raise awareness and improve early diagnosis, survival, and quality of life.
A University of Illinois study discovered that cadherin proteins can sense mechanical stress and alter cell communication, promoting tissue growth and tumorigenesis. The findings suggest a potential mechanism for preventing certain types of tissue growth by mutating cadherin molecules.
Researchers have developed a new therapeutic approach to block mutated RAS proteins, which are frequently found in cancers. The method, using small molecules, has the potential to work with multiple mutant forms of RAS in various types of cancers, including pancreatic, lung, and colorectal cancers.
Researchers at Massachusetts General Hospital developed a safe and effective strategy to treat glioblastoma using short bursts of radiation therapy and nanoparticle-based immunotherapy. The combined approach suppresses tumor growth, induces anti-tumor immunity, and prolongs survival in animal models.
Researchers found that hyaluronic acid is not only present in pancreatic tumors but also serves as a nutrient source for cancer cells. This discovery indicates potential new treatments for pancreatic cancer by targeting the sugar scavenging pathway.
Researchers at Osaka University have made a breakthrough in understanding the molecular mechanisms behind Intrahepatic cholangiocarcinoma (ICC), a deadly form of liver cancer. By identifying TRAF3 and NIK as key players, they have uncovered potential therapeutic targets for novel ICC treatment.
Researchers found that zika virus injections destroyed brain tumors in mice and reduced tumor size in cerebral organoids, with immune cells alerting the system to its existence. This approach opens up prospects for virotherapy treatment of central nervous system tumors.
Researchers found that CBD shrinks glioblastoma tumors by reducing inflammation and restoring immune balance. The compound also suppresses key proteins involved in tumor growth and spread, making it a potential novel adjunct therapy for glioblastoma patients.
Researchers found that asthma causes immune cells to behave in a way that prevents brain tumor growth, suggesting a potential new therapeutic approach. The findings suggest reprogramming T cells to act like those in asthma patients could be a new treatment for brain tumors.
Researchers at the University of Gothenburg have successfully treated high-risk neuroblastoma in mice using a combination of precision medicines, showing potential for a curative treatment. The study's results suggest that patients with this form of childhood cancer may benefit from drug treatment with ATR inhibitors.
CNIO researchers have identified a new biomarker for early melanoma metastasis, proposing the use of NGFR to predict disease prognosis and define risk groups. Blocking NGFR drastically reduces metastasis in mice, paving the way for a potential first treatment to tackle metastasis in its earliest stages.
The Lef1 gene is found to suppress the development and growth of colorectal cancer by restricting cancer stem cell niches. Blocking this gene leads to increased tumor stem cell niches and accelerated tumor growth.
According to experts, half of patients with two common subtypes of advanced breast cancer may live for five years or longer. The new guidelines also aim to improve treatment options for triple-negative breast cancer patients.
Researchers at Children's Hospital of Philadelphia have developed a novel therapy that targets proteins essential for tumor growth and survival. Using a multi-omics approach, they identified peptides unique to neuroblastoma tumors, which are then targeted by peptide-centric chimeric antigen receptors (PC-CARs).
Metastases in malignant melanoma can use an alternative process to access the circulatory system, where a blood vessel divides into two parallel vessels. This finding challenges traditional research on tumor growth and may lead to new treatment options for metastatic cancer.
A new study finds that high-dose radiation therapy can lengthen progression-free survival for people with advanced lung cancer when systemic therapy has not fully halted tumor growth or spread. Stereotactic body radiation therapy (SBRT) shows promise in treating oligoprogressive, metastatic lung and breast cancer.
Researchers at MIT develop a method to decode images of cells in a tissue to determine its phase, which can indicate its developmental stage or cancer progression. The technique uses triangular order parameters to characterize tissue states, allowing for quicker and less invasive diagnoses.
A new study from MIT reveals that calorie-restricted diets slow tumor growth in mice by reducing fatty acid availability, while ketogenic diets have limited effect. The findings offer insight into how dietary interventions might be combined with existing or emerging drugs to help patients with cancer.
A novel therapy concept allows tumor cells to produce a protein that blocks CD47 and activates immune cells. This approach eradicates tumors by macrophage and NK cell activation in a highly malignant human breast cancer model.
A peptide-drug conjugate called CBX-12 has been shown to enhance the efficacy of immune checkpoint inhibitors in preclinical cancer models by targeting the acidic environment of cancer cells. The treatment exhibited significantly delayed tumor growth, improved survival, and complete tumor regressions compared to immunotherapy alone.
A clinical trial found that obese prostate cancer patients who underwent regular exercise training for 12 weeks had increased levels of anti-cancer myokines, which suppressed tumour growth and helped fight cancerous cells. The study suggests exercise may be a key weapon in cancer patients' battle against the disease.
A new treatment approach targets angiogenesis, inflammation, and oxidative stress in glioblastoma multiforme, reducing tumor volume and growth by up to 89%. The combination of LAU-0901, Elovanoids, and Avastin shows promise in improving survival rates for patients with this deadly cancer.
Researchers at UArizona Health Sciences have discovered a mechanism that tumors use to keep blood vessels growing, driving cancer growth and invasion. Targeting this mechanism with drugs could lead to more effective cancer treatments by overcoming drug resistance.
Researchers found that antidepressants inhibit the growth of pancreatic and colon cancers in mice by blocking a mechanism used by cancer cells to evade the immune system. The findings suggest a promising approach for combining antidepressant drugs with immunotherapy to treat incurable cancers.
A study by MedUni Wien researchers has discovered that the transcription factor BATF3 and its target genes play a crucial role in the growth of tumour cells in anaplastic large cell lymphoma. The findings suggest that targeting the IL-2R system could be an effective therapeutic approach, with promising results in animal models.
Researchers develop a novel cell reprogramming strategy to transform glioma cells into non-proliferative neurons. This approach shows promise in slowing down the growth of GBMs and overcoming harmful side effects of conventional treatments.
Recent study by Okayama University researchers reveals three photoinitiators cause faster increase in breast tumor growth in mice, with tamoxifen pretreatment reducing toxicity. The findings suggest photoinitiators could act as hormonal disruptions, raising concerns for patients and healthy individuals.
Researchers have uncovered a weakness in the key enzyme that solid tumour cancer cells rely on to adapt and survive when oxygen levels are low. Inhibiting this enzyme, called Carbonic Anhydrase IX (CAIX), can effectively stop cancer cell growth.
A population-based cohort study in Canada identified mortality patterns for different types of neuroendocrine tumors (NETs), revealing varying risks of cancer-related and non-cancer death. The study found that small NETs can be safely monitored, while larger tumors may require more aggressive treatment.
Researchers at the University of Alabama at Birmingham have identified DOT1L as a potential therapeutic target for ovarian cancer. Inhibitors of the DOT1L enzyme showed promise in reducing tumor growth and improving survival rates by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.
Cells undergoing EMT promote tumor growth by acquiring an endothelial phenotype or contributing to vascular transdifferentiation. FOXC2 is crucial for these processes.
A recent study published in the Oncogene Journal revealed that targeting HIF-1α significantly inhibited melanoma growth and amplified immune cell infiltration into tumour microenvironment. The discovery provides a valuable new target for making resistant melanomas more vulnerable to available anti-cancer treatments.
Researchers at the University of Texas M.D. Anderson Cancer Center have discovered that targeting the mitochondrial enzyme DHODH can induce ferroptosis and suppress tumor growth in cancer cells. The study suggests a new therapeutic strategy for inducing ferroptosis, which could have broad implications for treating various types of cancer.
Researchers found that autophagy selectively degrades PKA inhibitory subunit RIa, promoting mitochondrial metabolism and tumor cell growth. Suppression of AKAP11 levels in tumor cells prevents degradation and blocks PKA activation, inhibiting tumor cell growth.
A high-fat diet is associated with increased risk of late-onset colorectal cancer, particularly in obese female mice. The study reveals that excess body weight leads to tumor growth through inflammation, insulin-like growth factor release, and polarization of macrophages.
Researchers found that time-restricted feeding, a form of intermittent fasting aligned with circadian rhythms, improved metabolic health and reduced tumor growth in mice with obesity-driven postmenopausal breast cancer. Elevated insulin levels drove accelerated tumor growth, which was mitigated by reducing insulin levels.
Researchers at Duke University developed a predictive theory for tumor growth that approaches the subject from a new point of view, using thermodynamics and physical space. The results demonstrate how a tumor's growth is directly tied to its need to create greater access to flowing nutrients and conduits for removing refuse.
A team of engineers at Rensselaer Polytechnic Institute developed an in vitro lymphatic vessel model to study tumor emboli growth. Researchers found that the model showed different growth behaviors based on cell type, linked to force generation capability, and has implications for therapeutic design.
Dr. Benjamin Tu's research on cellular roles of small molecule metabolites has led to the discovery of a unique pathway supporting cancerous cell growth. His work challenges the long-held belief that metabolites are merely passive in their function, unveiling that they may drive key cellular processes.
Scientists have identified a new metabolic vulnerability in highly aggressive non-small cell lung cancer (NSCLC) tumors containing mutations in KRAS and LKB1. The hexosamine biosynthesis pathway is activated in these tumors, providing a potential target for therapy.
Researchers found that CRYM protein binds to hormone T3 and blocks cell membrane formation, inhibiting tumour growth. Lower CRYM levels are associated with poor prognosis.
Sertraline's anti-cancer activity is attributed to its ability to inhibit the production of serine and glycine, two amino acids that stimulate cancer cell growth. The substance has shown promise in inhibiting breast cancer cell growth when used in combination with other therapies.
Researchers found that chronic jet lag alters the microenvironment surrounding tumor cells, making it favorable for tumor growth, while hindering the body's natural immune defenses. This study adds to the growing scientific field of circadian disruption on health and wellbeing.
Research published in Nature Precision Oncology reveals that honeybee venom and its compound melittin rapidly destroy triple-negative and HER2-enriched breast cancer cells. The venom's potency allows for selective cell death with minimal effects on normal cells.
A team of scientists from UC San Diego identified a metabolic switch that decreases tumor growth in mice by restricting dietary amino acids. They found that restricting serine and glycine led to the production of toxic lipids that slow cancer progression.
Researchers found that TMEM165 expression levels alter N-linked glycosylation, promoting the invasion and growth of breast cancer cells. This study suggests a novel role for TMEM165 as a driver of tumor invasion and identifies it as a potential biomarker for breast carcinoma.
A study by Queen Mary University of London uncovers novel pathways controlling cancer progression, identifying Rac1 as a critical player in MET-driven processes. The findings may pave the way for more efficacious treatment regimens by targeting MET, PI3K, and mTOR.
A new study from Washington University School of Medicine has found that brain tumors in children with NF1 are driven by nearby noncancerous neurons and immune cells. The researchers discovered that targeting immune cells slows tumor growth in mice, pointing to potential new treatments.
Establishing an inducible BCL6 knock-out model allows studying the phenotype of BCL6 loss in DLBCL xenografts in vivo. The study demonstrates significant tumor growth inhibition and initial tumor stasis followed by slow tumor growth kinetics upon treatment with BCL6 degraders.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that prebiotics mucin and inulin slowed melanoma growth in mice by enhancing anti-tumor immunity. The study suggests a potential benefit of prebiotics in treating cancer or augmenting current therapies.
Researchers have discovered that inhibiting p38 reduces the growth of lung tumors in genetic mouse models. Lower levels of p38 in tumors are associated with a more favorable prognosis for patients.
Researchers at Boston University School of Medicine have discovered the protein c-Cbl has the ability to degrade PD-1, a critical immune checkpoint that helps cancer cells evade the immune system. This finding may lead to new therapies targeting c-Cbl to treat certain types of cancer, including melanoma and non-small lung cancer.
Researchers have identified a key protein, Importin-11, that transports the cancer-causing protein βcatenin into the nucleus of colon cancer cells. Inhibiting this transport step could block the growth of most colorectal cancers caused by elevated βcatenin levels.
Fibroblasts play a crucial role in wound healing but also facilitate tumor growth and metastases in breast cancer. Inhibiting inflammatory signaling pathways may prevent metastatic relapse, say researchers from Tel Aviv University.
Researchers at Stanford and UC-San Francisco have developed an experimental drug that targets lung cancer by neutralizing a single protein, slowing its growth. The decoy version of the receptor protein was engineered to preferentially bind to the protein, repelling other proteins involved in tumor growth.
Researchers at UNC Lineberger Comprehensive Cancer Center have identified a potential approach to block medulloblastoma growth by targeting the GSK-3 signaling pathway. By blocking this pathway, they may be able to control tumor growth and reduce debilitating side effects from radiation and chemotherapy.
A new study using big data reveals that many fundamental features of life, such as metabolism and growth, follow consistent relationships with body size across all creatures. This challenges the Metabolic Theory of Ecology and suggests a deep understanding of universal laws governing life's diversity.
Researchers at UNC Lineberger Comprehensive Cancer Center discovered a hyperactive cell signal contributing to tumor growth in aggressive blood cancer. They developed an experimental therapeutic compound, UNC3810A, that targeted and slowed tumor growth by blocking the hyperactive Tyro3 protein.
Researchers have identified an enzyme called LPCAT1 that plays a key role in tumor growth by changing the phospholipid composition of cancer cells' plasma membranes. When genetically depleted in mice, malignancies shrank dramatically, suggesting LPCAT1 as a potential new drug target for various cancer types.
Researchers at the University of Pennsylvania School of Medicine have identified a new pathway that works as a partner to MYC and may be its Achilles' Heel. By blocking the ATF4 gene, cancer cells produce too much protein and die due to stress. This finding could lead to a new therapeutic approach using existing inhibitors.